Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB)... This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.
- Mechanism
- Curator reviewed · 4 references
Tegoprazan works as a potassium-competitive acid blocker that is potent and highly selective. Its mechanism of action is different from that of the proton-pump inhibitors as this drug does not require conversion into an active form and can directly inhibit H+/K+‐ATPase in a reversible and K+‐competitive way. This is because it is an acid-resistant weak base with the ability to remain in the highly acidic canaliculi of gastric parietal cells.
- Formula / weight
- C20H19F2N3O3 · 387.387 g/mol (avg)
- Also known as
- IN-A001 · K-CAB · RQ-00000004
- Code names
- CJ-12420 · LXI-15028
Resolves to
CLIQCDHNPDMGSL-HNNXBMFYSA-NSMILESCN(C)C(=O)C1=CC(O[C@H]2CCOC3=CC(F)=CC(F)=C23)=C2NC(C)=NC2=C1What you can answer from here — as of April 30, 2021
Which companies are running trials of Tegoprazan, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account